Apolipoprotein B-100
"Apolipoprotein B-100" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 513-kDa protein synthesized in the LIVER. It serves as the major structural protein of low-density lipoproteins (LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL). It is the ligand for the LDL receptor (RECEPTORS, LDL) that promotes cellular binding and internalization of LDL particles.
| Descriptor ID |
D053299
|
| MeSH Number(s) |
D10.532.091.300.249 D12.776.070.400.300.249 D12.776.521.120.300.249
|
| Concept/Terms |
Apolipoprotein B-100- Apolipoprotein B-100
- Apolipoprotein B 100
- ApoB-100
- ApoB 100
- Apo B-100
- Apo B 100
- Apo-B-100
|
Below are MeSH descriptors whose meaning is more general than "Apolipoprotein B-100".
Below are MeSH descriptors whose meaning is more specific than "Apolipoprotein B-100".
This graph shows the total number of publications written about "Apolipoprotein B-100" by people in this website by year, and whether "Apolipoprotein B-100" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2001 | 0 | 2 | 2 | | 2004 | 0 | 1 | 1 | | 2009 | 1 | 0 | 1 | | 2016 | 1 | 1 | 2 | | 2024 | 0 | 1 | 1 | | 2025 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Apolipoprotein B-100" by people in Profiles.
-
Tsimikas S, Szarek M, Cobbaert CM, Romijn F, Jukema JW, Bhatt DL, Bittner VA, Diaz R, Fazio S, Garon G, Yuan C, Gong XM, Goodman SG, White HD, Witztum JL, Steg PG, Schwartz GG. Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome. Circulation. 2025 Dec 16; 152(24):1666-1678.
-
Wu X, Wilke M, Batara J, Proctor S, Cree M, Ghosh M, Raggi P, Windram J, Becher H, Vine D. Atherogenic ApoB-dyslipidemia, atherosclerotic cardiovascular disease, cardiac dysfunction and remodeling in high-risk young women with and without polycystic ovary syndrome: A pilot study. Front Endocrinol (Lausanne). 2025; 16:1520922.
-
Kothari V, Ho TWW, Cabodevilla AG, He Y, Kramer F, Shimizu-Albergine M, Kanter JE, Snell-Bergeon J, Fisher EA, Shao B, Heinecke JW, Wobbrock JO, Lee WL, Goldberg IJ, Vaisar T, Bornfeldt KE. Imbalance of APOB Lipoproteins and Large HDL in Type 1 Diabetes Drives Atherosclerosis. Circ Res. 2024 Jul 05; 135(2):335-349.
-
Natarajan P, Bis JC, Bielak LF, Cox AJ, Dörr M, Feitosa MF, Franceschini N, Guo X, Hwang SJ, Isaacs A, Jhun MA, Kavousi M, Li-Gao R, Lyytikäinen LP, Marioni RE, Schminke U, Stitziel NO, Tada H, van Setten J, Smith AV, Vojinovic D, Yanek LR, Yao J, Yerges-Armstrong LM, Amin N, Baber U, Borecki IB, Carr JJ, Chen YI, Cupples LA, de Jong PA, de Koning H, de Vos BD, Demirkan A, Fuster V, Franco OH, Goodarzi MO, Harris TB, Heckbert SR, Heiss G, Hoffmann U, Hofman A, I?gum I, Jukema JW, Kähönen M, Kardia SL, Kral BG, Launer LJ, Massaro J, Mehran R, Mitchell BD, Mosley TH, de Mutsert R, Newman AB, Nguyen KD, North KE, O'Connell JR, Oudkerk M, Pankow JS, Peloso GM, Post W, Province MA, Raffield LM, Raitakari OT, Reilly DF, Rivadeneira F, Rosendaal F, Sartori S, Taylor KD, Teumer A, Trompet S, Turner ST, Uitterlinden AG, Vaidya D, van der Lugt A, Völker U, Wardlaw JM, Wassel CL, Weiss S, Wojczynski MK, Becker DM, Becker LC, Boerwinkle E, Bowden DW, Deary IJ, Dehghan A, Felix SB, Gudnason V, Lehtimäki T, Mathias R, Mook-Kanamori DO, Psaty BM, Rader DJ, Rotter JI, Wilson JG, van Duijn CM, Völzke H, Kathiresan S, Peyser PA, O'Donnell CJ. Multiethnic Exome-Wide Association Study of Subclinical Atherosclerosis. Circ Cardiovasc Genet. 2016 Dec; 9(6):511-520.
-
Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, Eckel RH, Cannon CP. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13; 134(24):1931-1943.
-
Sniderman AD, Islam S, McQueen M, Pencina M, Furberg CD, Thanassoulis G, Yusuf S. Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol. J Am Heart Assoc. 2016 10 13; 5(10).
-
Byers T, Goff D. Response. J Natl Cancer Inst. 2015 Oct; 107(10).
-
Byers T, Goff D. Breast cancer, heart disease, and whispering "fire" in a public theater. J Natl Cancer Inst. 2015 May; 107(5).
-
Stewart BJ, Roede JR, Doorn JA, Petersen DR. Lipid aldehyde-mediated cross-linking of apolipoprotein B-100 inhibits secretion from HepG2 cells. Biochim Biophys Acta. 2009 Aug; 1791(8):772-80.
-
Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004 Sep 14; 110(11):1406-12.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|